EcoR1 Capital, LLC is an employee-owned investment advisory firm based in San Francisco, California, founded in 2012. Specializing in the biotechnology sector, EcoR1 Capital focuses on identifying and evaluating innovative therapeutic solutions that can significantly enhance patient outcomes. The firm employs a long/short investment strategy primarily within the public equity markets of the United States, while also managing separate client-focused equity and fixed income portfolios. By investing in biotech companies that offer promising new treatments for untreated diseases, EcoR1 Capital aims to advance medical research and build upon the innovative contributions of its predecessors in the healthcare and life sciences fields.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Attovia Therapeutics
Series B in 2024
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.